https://orcid.org/0000-0002-3623-0743
![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy’s efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy’s availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT’s effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.
Acknowledgment
The authors are grateful to Prof. Mohammed S. Razzaque, MBBS, Ph.D. of Lake Erie College of Osteopathic Medicine (Pennsylvania, USA) for providing useful suggestions. Additionally, the authors are very grateful to Professor (Dr.) Md Zakirul Islam, Professor, and Vice-Principal, Eastern Medical College, Cumilla, Bangladesh for his kind support to develop high-resolution figures.
Special Note
Nevertheless, the Indian Council of Medical Research put out an open-label phase-2 multicenter randomized controlled trial (placid trial) on October 22, 2020. Their research concluded CPT was unable to minimize COVID-19, both morbidity and mortality.Citation269
Article Highlights
CPT possesses the potential to reduce morbidity and mortality COVID-19.
CPT induced side effects in treated patients, and risk-benefit assessment should identify potential recipients.
If sensitivity is not maintained, possible health risks due to transfusion-associated contaminations overwhelm the benefits.
The low ratio of cured cases to plasma donors leads to unavailability and inaccessibility.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest for this work. The authors declare that they do not have any financial involvement or affiliations with any organization, association, or entity which has a direct or indirect relationship with the subject matter or materials presented in this article. This also includes honoraria, expert testimony, employment, ownership of stocks or options, patents or grants received or pending, or royalties.